Mortality, Readmission Low With COVID-19 Discharge on Home Oxygen
All-cause mortality rate 1.3 percent; 30-day readmission rate 8.5 percent among 621 patients discharged on home oxygen
All-cause mortality rate 1.3 percent; 30-day readmission rate 8.5 percent among 621 patients discharged on home oxygen
Short-course antibiotic therapy comparable to standard care for community-acquired pneumonia
The ACIP emphasizes the importance of routine vaccinations during the pandemic to prevent diseases.
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
The 20vPnC vaccine candidate consists of capsular polysaccharide conjugates for the 13 serotypes included in Prevnar 13, along with 7 additional serotypes that cause invasive pneumococcal disease.
Use of ACE-I/ARB vs nonuse linked to lower mortality for those hospitalized with flu, pneumonia.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
Patients with heart failure receiving flu, pneumonia vaccinations have lower in-hospital mortality